GB18 Injection Phase I Tumor Cachexia Trial

NLM registered a new Phase I clinical trial on ClinicalTrials.gov for GB18 Injection as a treatment for tumor cachexia, a wasting syndrome associated with cancer. The trial is classified as Phase I (early-stage safety evaluation), non-randomized, and expects to enroll approximately 24 adult participants at a single US site.

Affected parties should note this trial represents an early-stage drug development milestone. Healthcare providers treating cachexia patients may consider referring suitable candidates. Pharmaceutical researchers should ensure their cachexia programs maintain current registrations. This registration has no immediate compliance obligations but establishes the trial's public record for regulatory transparency.